Skip to main content

Advertisement

SpringerLink
Log in

The Twin Epidemics of Tuberculosis and HIV

  • HIV/AIDS (R MacArthur, Section Editor)
  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

The deadly combination of tuberculosis (TB) and human immunodeficiency virus (HIV) currently ravaging the world, taking a toll of about 0.35 million people every year, is one of the major public health crises of the decade. Throughout the course of HIV infection, the risk of acquisition, reactivation, and reinfection of TB keeps increasing substantially as the immune deficiency progresses. TB coinfected patients inadvertently facilitate HIV infection by release of the proinflammatory cytokines and overexpression of coreceptors CXCR4 and CCR5; thereby, the progression of each is facilitated. The difficulties in diagnosing active tuberculosis in HIV-infected individuals poses a great challenge that is further complicated by the challenges in identification of latent TB infection, creating a setback to preventive therapy. Furthermore, prescribing antituberculous therapy and antiretroviral therapy together poses several management challenges, including drug interactions, added toxicities, and TB immune reconstitution inflammatory syndrome. The current approach to diagnosis, prevention, and treatment strategies in TB and HIV coinfected individuals, along with epidemiology and overview of pathogenetic interplay of both microbes, is reviewed here.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Mayer KH, Hamilton CD. Synergistic pandemics: confronting the global HIV and tuberculosis epidemics. Clin Infect Dis. 2010;50:S67–70.

    Article  PubMed  Google Scholar 

  2. Getahun H, Gunneberg C, Granich R, Nunn P. HIV infection associated tuberculosis: the epidemiology and the response. Clin Infect Dis. 2010;50:S201–7.

    Article  PubMed  Google Scholar 

  3. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989;320:545–50.

    Article  PubMed  CAS  Google Scholar 

  4. Aaron L, Saadoun D, Calatroni I, Launay O, et al. Tuberculosis in HIV-infected patients: a comprehensive review. Clin Microbiol Infect. 2004;10:388–98.

    Article  PubMed  CAS  Google Scholar 

  5. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, et al. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med. 1995;151:129–35.

    PubMed  CAS  Google Scholar 

  6. Modjarrad K, Vermund SH. Effect of treating co-infections on HIV-1 viral load: a systematic review. Lancet Infect Dis. 2010;10:455–63.

    Article  PubMed  Google Scholar 

  7. World Health Organization report. Global Tuberculosis Control. 2011. http://www.who.int/tb/publications/global_report/en/index.html.

  8. World Health Organization. Towards universal access: Global HIV/AIDS response – Epidemic update and health sector progress Towards Universal Access. Progress Report 2011. http://www.who.int/hiv/pub/progress_report2011/summary_en.pdf.

  9. Havlir DV, Getahun H, Sanne I, Nunn P. Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA. 2008;300:423–30.

    Article  PubMed  CAS  Google Scholar 

  10. Lawn SD, Myer L, Edwards D, Bekker LG, Wood R. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS. 2009;23:1717–25.

    Article  PubMed  Google Scholar 

  11. Pawlowski A, Jansson M, Skold M, Rottenberg ME, Kallenius G. Tuberculosis and HIV Co-Infection. PLoS Pathog. 2012;8(2):e1002464.

    Article  PubMed  CAS  Google Scholar 

  12. Cain KP, McCarthy KD, Heilig CM, et al. An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med. 2010;362:707–16.

    Article  PubMed  CAS  Google Scholar 

  13. World Health Organization. Improving the diagnosis and treatment of smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents: Recommendations for HIV-prevalent and resource-constrained settings. Available at: http://www.who.int/tb/publications/2006/tbhiv_recommendations.pdf.

  14. Bassett IV, Wang B, Chetty S, Giddy J, Losina E, Mazibuko M, et al. Intensive tuberculosis screening for HIV-infected patients starting ART in Durban, South Africa. Clin Infect Dis. 2010;51(7):823–9.

    Article  PubMed  Google Scholar 

  15. • Getahun H, Kittikraisak W, Heilig CM, Corbett EL, Ayles H, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med. 2011;8(1):e1000391. doi:10.1371/journal.pmed.1000391. This meta-analysis has derived a practical algorithm based on symptom screening for active TB that has a good sensitivity and very high negative predictive value.

    Article  PubMed  Google Scholar 

  16. Monkongdee P, McCarthy KD, Cain KP, Tasaneeyapan T, Nguyen HD, Nguyen TN, et al. Yield of acid-fast smear and mycobacterial culture for tuberculosis diagnosis in people with human immunodeficiency virus. Am J Respir Crit Care Med. 2009;180:903–8.

    Article  PubMed  Google Scholar 

  17. Getahun H, Harrington M, O’Brien R, Nunn P. Diagnosis of smear negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet. 2007;369:2042–9.

    Article  PubMed  Google Scholar 

  18. Perlman DC, Leung CC, Yew WW. Diagnosing tuberculosis in patients with HIV: do we know enough? Am J Respir Crit Care Med. 2009;180:800–1.

    Article  PubMed  Google Scholar 

  19. Steingart KR, Ng V, Henry M, Hopewell PC, Ramsay A, et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis. 2006;6:664–74.

    Article  PubMed  Google Scholar 

  20. Padyana M, Bhat RV, Dinesha M, Nawaz A. HIV-tuberculosis: a study of chest x-ray patterns in relation to CD4 count. N Am J Med Sci. 2012;4(5):221–5.

    Article  PubMed  Google Scholar 

  21. Daley P, Michael JS, Hmar P, Latha A, Chordia P, Mathai D, et al. Blinded evaluation of commercial urinary lipoarabinomannan for active tuberculosis: a pilot study. Int J Tuberc Lung Dis. 2009;13(8):989–95.

    PubMed  CAS  Google Scholar 

  22. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis. 2012;12(3):201–9.

    Article  PubMed  Google Scholar 

  23. Gil-Setas A, Torroba L, Fernandez JL, Martinez-Artola V, Olite J. Evaluation of the MB/BacT system compared with Middlebrook 7H11 and Lowenstein-Jensen media for detection and recovery of mycobacteria from clinical specimens; Clin. Microbiol Infect. 2004;10:224–8.

    Article  CAS  Google Scholar 

  24. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363:1005–15.

    Article  PubMed  CAS  Google Scholar 

  25. • WHO policy on collaborative TB/HIV activities. Guidelines for national programmes and other stakeholders. http://whqlibdoc.who.int/publications/2012/9789241503006_eng.pdf. WHO’s strong recommendation for Xpert MTB/RIF assay as the initial diagnostic test for evaluation of active TB in HIV-infected individuals.

  26. McNerney R, Daley P. Towards a point-of-care test for active tuberculosis: obstacles and opportunities. Nat Rev Microbiol. 2011;9:204–13.

    Article  PubMed  CAS  Google Scholar 

  27. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet. 2002;359(9323):2059–64.

    Article  PubMed  Google Scholar 

  28. Perriens JH, St Louis ME, Mukadi YB, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire: a controlled trial of treatment for either 6 or 12 months. N Engl J Med. 1995;332:779–84.

    Article  PubMed  CAS  Google Scholar 

  29. Fitzgerald DW, Desvarieux M, Severe P, Joseph P, Johnson Jr WD, Pape JW. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomized trial. Lancet. 2000;356:1470–4.

    Article  PubMed  CAS  Google Scholar 

  30. Narayanan S, Swaminathan S, Supply P, Shanmugam S, Narendran G, Hari L, et al. Impact of HIV infection on the recurrence of tuberculosis in South India. J Infect Dis. 2010;201:691–703.

    Article  PubMed  Google Scholar 

  31. Chang KC, Leung CC, Yew WW, Ho SC, Tam CM. A nested casecontrol study on treatment-related risk factors for early relapse of tuberculosis. Am J Respir Crit Care Med. 2004;170(10):1124–30.

    Article  PubMed  Google Scholar 

  32. Chang KC, Leung CC, Yew WW, Chan SL, Tam CM. Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis. Am J Respir Crit Care Med. 2006;174(10):1153–8.

    Article  PubMed  Google Scholar 

  33. • Ahmad Khan F, Minion J, Al-Motairi A, Benedetti A, Harries AD, Menzies D. An Updated Systematic Review and Meta-analysis on the Treatment of Active Tuberculosis in Patients With HIV Infection. Clin Infect Dis. 2012;55(8):1154–63. An updated meta-analysis conclusively showing reduced risk of relapse with each of the interventions of daily ATT, rifampicin throughout treatment, 9 months duration, and concurrent ART.

  34. Ribera E, Pou L, Lopez RM, Crespo M, Falco V, Ocaña I, et al. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquir Immune Defic Syndr. 2001;28(5):450–3.

    PubMed  CAS  Google Scholar 

  35. Schwander S, Rüsch-Gerdes S, Mateega A, Lutalo T, Tugume S, Kityo C, et al. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis. Tuber Lung Dis. 1995;76(3):210–8.

    Article  PubMed  CAS  Google Scholar 

  36. Perucca E, Grimaldi R, Frigo GM, Sardi A, Mönig H, Ohnhaus EE. Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects. Eur J Clin Pharmacol. 1988;34(6):595–9.

    Article  PubMed  CAS  Google Scholar 

  37. Burman WJ, Gallicano K, Peloquin C. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis. Clin Infect Dis. 1999;28(3):419–29. quiz 430.

    Article  PubMed  CAS  Google Scholar 

  38. Narita M, Stambaugh JJ, Hollender ES, Jones D, Pitchenik AE, Ashkin D. Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis. Clin Infect Dis. 2000;30(5):779–83.

    Article  PubMed  CAS  Google Scholar 

  39. Sun E, Heath-Chiozzi M. Concurrent ritonavir and rifabutin increases risk of rifabutin-associated adverse events. Paper presented at: XI International Conference on AIDS. 1996.

  40. CDC | TB | Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis | References [Internet]. [cited 2012 Aug 26]. Available from:http://www.cdc.gov/tb/publications/guidelines/tb_hiv_drugs/references.htm#42.

  41. • Naiker S, Conolly C. Pharmacokinetic evaluation of different rifabutin dosing strategies in african TB patients on Lopinavir/ritonavir-based ART [Internet]. [cited 2012 Sep 4]. Available from: http://www.retroconference.org/2011/Abstracts/41692.htm. A daily dose of rifabutin (150 mg) may be administered in patients on boosted PIs to avoid underdosing of the former.

  42. ISRCTN13074752 - Europe - Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Rifabutin Pharmacokinetics (PK) substudy [Internet]. [cited 2012 Sep 4]. Available from: http://www.controlled-trials.com/isrctn/pf/13074752.

  43. Edmunds-Ogbuokiri T. An in-depth look at the challenges of prescribing maraviroc. HIV Clin. 2008;20:9–11.

    PubMed  Google Scholar 

  44. Wenning LA, Hanley WD, Brainard DM, Petry AS, Ghosh K, Jin B, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2009;53(7):2852–6.

    Article  PubMed  CAS  Google Scholar 

  45. Blanc F-X, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365(16):1471–81.

    Article  PubMed  CAS  Google Scholar 

  46. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010;362(8):697–706.

    Article  PubMed  CAS  Google Scholar 

  47. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;365(16):1482–91.

    Article  PubMed  CAS  Google Scholar 

  48. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS. 2005;19(18):2109–16.

    Article  PubMed  Google Scholar 

  49. Jones JL, Hanson DL, Dworkin MS, et al. HIV-associated tuberculosis in the era of highly active antiretroviral therapy. The Adult/Adolescent Spectrum of HIV Disease Group. Int J Tuberc Lung Dis. 2000;4(11):1026–31.

    PubMed  CAS  Google Scholar 

  50. Lawn SD, Myer L, Bekker LG, et al. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS. 2006;20(12):1605–12.

    Article  PubMed  Google Scholar 

  51. Brinkhof MW, Egger M, Boulle A, et al. Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis. 2007;45(11):1518–21.

    Article  PubMed  Google Scholar 

  52. Moh R, Danel C, Messou E, et al. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS. 2007;21(18):2483–91.

    Article  PubMed  Google Scholar 

  53. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008;8(8):516–23.

    Article  PubMed  Google Scholar 

  54. Burman W, Jones BE. Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. Am J Respir Crit Care Med. 2001;164(1):7–12.

    PubMed  CAS  Google Scholar 

  55. Robertson J, Meier M, Wall J, et al. Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis. 2006;42(11):1639–46.

    Article  PubMed  Google Scholar 

  56. Manabe Y, Campbell JD, Sydnor E, et al. Immune reconstitution inflammatory syndrome: risk factors and treatment implications. J Acquir Immune Defic Syndr. 2007;46(4):456–62.

    Article  PubMed  CAS  Google Scholar 

  57. Price P, Morahan G, Huang D, et al. Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases. AIDS. 2002;16(15):2043–7.

    Article  PubMed  CAS  Google Scholar 

  58. Grant P, Komarow L, Andersen J, et al. Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PLoS One. 2010;5(7):e11416.

    Article  PubMed  Google Scholar 

  59. Lederman MM. Immune restoration and CD4+ T-cell function with antiretroviral therapies. AIDS. 2001;15:S11–5.

    Article  PubMed  CAS  Google Scholar 

  60. Bourgarit A, Carcelain G, Martinez V, Lascoux C, Delcey V, et al. Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS. 2006;20:F1–7.

    Article  PubMed  CAS  Google Scholar 

  61. French MA. HIV/AIDS. Immune reconstitution inflammatory syndrome: a reappraisal. Clin Infect Dis. 2009;48:101–7.

    Article  PubMed  Google Scholar 

  62. Elzi L, Schlegel M, Weber R, et al. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis. 2007;44:94.

    Article  PubMed  Google Scholar 

  63. Samandari T, Agizew TB, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377:1588.

    Article  PubMed  CAS  Google Scholar 

  64. • Lawn SD, Harries AD, Meintjes G, Getahun H, Havlir DV, Wood R. Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2012;26(17):2121–33. Earlier initiation of ART in PLHIV is likely to reduce TB-related mortality.

  65. • Suthar AB, Lawn SD, Del Amo J, Getahun H, Dye C, Sculier D, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med. 2012;9(7):e1001270. Epub 2012 Jul 24. Earlier initiation of ART in PLHIV is likely to reduce incidence of TB.

    Article  PubMed  CAS  Google Scholar 

  66. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010;CD000171. Available at: http://www.escriber.com/userfiles/ccoch/file/CD000171.pdf.

  67. • World Health Organization. WHO Three I's Meeting, World Health Organization, Geneva, 2009. http://www.who.int/tb/publications/2009/who_3Is_meeting_report.pdf. 3Is for prevention of active TB in HIV-infected individuals as recommended by WHO.

  68. Menzies D, Jahdali HA, Otaibi BA. Recent developments in treatment of latent tuberculosis infection. Indian J Med Res. 2011;133:257–66.

    PubMed  CAS  Google Scholar 

  69. Howard AA and El-Sadr http://cid.oxfordjournals.org/content/50/Supplement_3/S238.long-aff-2 WM Integration of Tuberculosis and HIV Services in Sub-Saharan Africa: Lessons Learned. Clin Infect Dis. 2010; 50(Suppl 3): S238–S244. doi: 10.1086/651497.

  70. Innes C. Effectiveness of isoniazid preventive therapy in reducing mortality in patients on ART. 17th Conference on Retroviruses and Opportunistic Infections (CROI). [Abstract 102.] February 16–19, 2010; San Francisco, California.

  71. Luetkemeyer. Current Issues in the Diagnosis and Management of Tuberculosis and HIV Coinfection in the United States. Managing Tuberculosis in HIV Infection 2010;18(4):143–148 http://www.iasusa.org/pub/topics/2010/issue4/143.pdf.

  72. Jensen PA, Lambert LA, Iademarco MF, Ridzon R. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep. 2005;54(RR-17):1–141. for the Centers for Disease Control and Prevention.

    PubMed  Google Scholar 

  73. Bock NN, Jensen PA, Miller B, Nardell E. Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment. J Infect Dis. 2007;196 Suppl 1:S108–13. doi:10.1086/518661.

    Article  PubMed  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Department of Medicine 1 & Infectious Diseases, Christian Medical College, Vellore, 632004, India

    George M. Varghese, Jeshina Janardhanan, Ravikar Ralph & Ooriapadickal C. Abraham

Authors
  1. George M. Varghese
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeshina Janardhanan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ravikar Ralph
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ooriapadickal C. Abraham
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to George M. Varghese.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Varghese, G.M., Janardhanan, J., Ralph, R. et al. The Twin Epidemics of Tuberculosis and HIV. Curr Infect Dis Rep 15, 77–84 (2013). https://doi.org/10.1007/s11908-012-0311-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11908-012-0311-3

Keywords

Search

Navigation